EGFR and gastric cancer: Interestingly, a combination of an FGFR2 inhibitor and EGFR neutralizing antibody partially enhanced drug sensitivity of GC in vitro and in vivo, suggesting these RTKs may cause drug resistance in cancer cells under FGFR2 inhibition.